How to Buy Damora Therapeutics Stock
Damora Therapeutics Inc
Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases.
Damora Therapeutics stock last closed at $24.60, up 3.02% from the previous day, and has increased 743.91% in one year. It has overperformed other stocks in the Biotechnology industry by 7.42 percentage points. Damora Therapeutics stock is currently +904.08% from its 52-week low of $2.45, and -35.81% from its 52-week high of $38.33.
At the moment, there are 61.55M DMRA shares outstanding. The market value of DMRA is $1.51B. In the past 24 hours, 438,000 DMRA shares were traded.
How to Buy Damora Therapeutics Stock
Not sure how to invest in Damora Therapeutics stock? Here's how.
- Decide where to buy Damora Therapeutics stock: You need to decide on a stock brokerage, but don't worry - we've tested dozens of online stock brokerages and apps to help you choose where to buy Damora Therapeutics stock.
- Open a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Deposit funds into your brokerage account: Select your method of payment and add your information.
- Analyze Damora Therapeutics stock: The Damora Therapeutics ticker symbol is DMRA. Is Damora Therapeutics stock a good investment? Should you buy shares of DMRA? How do DMRA's underlying business fundamentals look? Do top analysts think Damora Therapeutics is a good buy? Why has DMRA's stock price moved recently? (Hint: Our stock market research tools can help you figure out if DMRA is a good stock to buy).
- Place your DMRA buy order: Decide if you will purchase DMRA shares at the current market price or use a limit order to purchase DMRA stock at a particular price.
- Get the latest news on your investment in DMRA: Create a watchlist to important updates regarding your position in Damora Therapeutics stock.
Step 1: Decide where to buy Damora Therapeutics stock
You need an online brokerage account to access the NASDAQ market and buy DMRA stock.
Our preferred brokerage: eToro
Based on our experience, eToro is the best place to buy stocks. Here's why:
- Invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
- Access to global markets: From Technology to Utilities, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading exchanges.
- Social investing: eToro has a community of more than 20 million users worldwide. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your share purchase by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Open a brokerage account
Now that you've chosen your brokerage, you need to fill out some personal information so you are able to invest in DMRA stock today.
How to Set Up a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal details to create a new trading account.
- Send your information by clicking the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your brokerage account
Now that you have opened your account on a investment app, you need to deposit funds:
Watch the video below if you need help transferring funds into your new investment account.
Step 4: Analyze Damora Therapeutics stock
Once you have figured out the best place to buy Damora Therapeutics stock, it's important to evaluate their stock prior to investing, so you can comprehend the risk and upside.
Overview of key DMRA info
Damora Therapeutics Fundamentals
WallStreetZen was designed to help everyday investors do more in-depth fundamental analysis.
You can see all of the due diligence checks on DMRA's stock page.
Is DMRA stock undervalued?
Investors use many financial metrics, analyses, models, and charts to gauge DMRA's true value.
Using relative valuations ratios:
- DMRA could be undervalued based on its P/E ratio of 4.66x, relative to Biotechnology industry P/E ratio of 16.99x
- DMRA could be undervalued based on its P/B ratio of 2.96x, relative to Biotechnology industry P/B ratio of 4.85x
You can do additional valuation analysis on DMRA's stock here.
Is DMRA a healthy company?
Positive Financial Indicators:
- DMRA has a low debt to equity ratio of 0.05.
- There are more short-term assets than short-term liabilities on the DMRA balance sheet.
- DMRA has $532.90M in cash and short term investments. This is sufficient to cover its annual cash burn of $24.89M.
- DMRA has cash burn of 24885000. It has sufficient cash and short-term investments to cover this for at least one year.
- There are more short-term assets than long-term liabilities on the DMRA balance sheet.
Negative Financial Indicators:
- Total DMRA debt is higher than 5 years ago, relative to shareholder equity.
Do Wall Street analysts think it's a good time to buy Damora Therapeutics stock
Out of 5 sell side analysts who give recommendations on DMRA, the consensus analyst rating on DMRA is a Strong Buy
Please keep in mind that analyst ratings are not recommendations, nor are they financial advice.
You can dive deeper into what analysts are projecting on the Damora Therapeutics stock forecast page.
DMRA Momentum
DMRA Revenue
Last year, DMRA earnings were -$235.09M. During the past 5 year, DMRA's earnings have gone up by -63.52% per year. This was slower than the Biotechnology industry average of 11.85%.
Dive into DMRA's earnings and revenue performance here.
Who is buying/selling DMRA?
In the last year, executives and large shareholders at DMRA have sold more shares than they have bought.
Lori Firmani, Chief Financial Officer of DMRA, was the latest DMRA insider to sell. They sold $2,890.35 worth of DMRA shares on Jan 2, 2026.
Get more info about who owns DMRA stock here.
Can I get consistent income from DMRA stock?
No, Damora Therapeutics doesn't provide an income stream by paying out dividends.
Get opinions from other investors
One of the major reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Place your DMRA buy order
There are two primary order types:
- Market order: A market order is an order to buy or sell a security at the best available price.
Market orders are generally the easiest way to buy. - Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
If you want to ensure you're buying or selling at an exact dollar amount limit, use a limit order.
Click the Open button and eToro will place your order.
If you require more help investing in stocks on eToro, click the how to video below:
Step 6: Get the latest news on your investment in DMRA
Now that you own some DMRA stock, you'll want to stay up-to-date on your new shares.
Put DMRA on a watchlist to get the latest updates about your DMRA stock.
DMRA Feed
How to Buy Stock in Damora Therapeutics
To summarize, here are the 6 steps to buy stock in Damora Therapeutics:
- Decide where to buy Damora Therapeutics stock
- Open a brokerage account
- Deposit funds into your brokerage account
- Analyze Damora Therapeutics stock
- Place your DMRA buy order
- Get the latest news on your investment in DMRA
If you are looking for a place to buy stocks, eToro is our favorite venue.
Get Started with eToro TodayIf you want to keep tabs on your new investment in Damora Therapeutics, click below.
Trending Articles
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.